Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass.
OBJECTIVE
To evaluate the possible protective effects of fenoldopam on renal function in patients undergoing cardiopulmonary bypass.


METHODS
Prospective, randomized trial.


METHODS
University teaching hospital.


METHODS
One hundred sixty consecutive patients with serum creatinine >1.5 mg/dL who underwent uncomplicated moderate hypothermic cardiopulmonary bypass for cardiac surgery.


METHODS
A random group of 80 patients was managed conventionally (group A), whereas another random group of 80 patients received continuous intravenous administration of low-dose fenoldopam (0.1-0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B).


RESULTS
An improvement of postoperative renal parameters were observed only in group B: preoperative serum creatinine 1.82 +/- 0.2 versus 1.43 +/- 0.73 postoperatively (p < 0.001), preoperative creatinine clearance 51.34 +/- 22.26 versus 67.14 +/- 18.55 postoperatively (p < 0.001).


CONCLUSIONS
In this study, fenoldopam was an effective agent in the prevention of renal dysfunction after cardiopulmonary bypass.
Caimmi
Philippe-Primo
PP
Department of Cardiac Surgery, University of East Piedmont, School of Medicine, Novara, Italy. philippeprimo.caimmi@tin.it
Pagani
Lorenzo
L
Micalizzi
Ezio
E
Fiume
Cosimo
C
Guani
Simona
S
Bernardi
Massimo
M
Parodi
Fillipo
F
Cordero
Gualtiero
G
Fregonara
Maura
M
Kapetanakis
Emmanouil
E
Panella
Massinniano
M
Degasperis
Carlo
C
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002315:Cardiopulmonary Bypass; D003404:Creatinine / Q000097:blood; D004232:Diuretics / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D018818:Fenoldopam / Q000008:administration & dosage / Q000627:therapeutic use*; D005431:Florida; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology*; D007674:Kidney Diseases / Q000517:prevention & control*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011446:Prospective Studies; D016896:Treatment Outcome; D014554:Urination / Q000187:drug effects / Q000502:physiology
D015415:Biomarkers; D004232:Diuretics; D018491:Dopamine Agonists; D005665:Furosemide; D003404:Creatinine; D018818:Fenoldopam; D011188:Potassium